-
Listing
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystem更多Seamless listing, trading, clearing and settlement for fixed income
-
Trading
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystem更多
Seamless listing, trading, clearing and settlement for fixed income
-
Clearing
Connecting Europe's Fixed Income MarketsOne connected fixed income ecosystem更多
Seamless listing, trading, clearing and settlement for fixed income
-
CSD
European CSD modelBuilding the CSD of Choice in Europe更多Euronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)更多The new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperNext generation of indices更多This white paper marks the second edition of Euronext’s Index Outlook series, a recurring publication designed to give investors deeper insight into our index innovation agenda and the structural forces shaping global markets.
-
About Euronext
Listing of Pharnext on Alternext
18/07/2016
Listing of Pharnext on Alternext
Prof. Daniel Cohen, MD, PhD, CEO & Founder, Pharnext, opens the trading day in Paris.
Pharnext specializes in the development of drugs based on PleotherapyTM for the treatment of severe, rare and common neurological diseases (including Alzheimer, Charcot-Marie Tooth disease, Parkinson's and amyotrophic lateral sclerosis). The company keeps creating new treatments by combining, at very low doses, molecules that are already tested for other diseases.
The group has a portfolio of 2 products in clinical development: PXT-3003 (treatment of the orphan disease Charcot-Marie-Tooth type 1A) and PXT-864 (Alzheimer's disease treatment).